scholarly journals TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol

BMJ Open ◽  
2018 ◽  
Vol 8 (1) ◽  
pp. e019463 ◽  
Author(s):  
Clara K Chow ◽  
Aravinda Thiagalingam ◽  
Karla Santo ◽  
Cindy Kok ◽  
Jay Thakkar ◽  
...  

BackgroundIdentifying simple, low-cost and scalable means of supporting lifestyle change and medication adherence for patients following a cardiovascular (CV) event is important.ObjectiveThe TEXTMEDS (TEXT messages to improve MEDication adherence and Secondary prevention) study aims to investigate whether a cardiac education and support programme sent via mobile phone text message improves medication adherence and risk factor levels in patients following an acute coronary syndrome (ACS).Study designA single-blind, multicentre, randomised clinical trial of 1400 patients after an ACS with 12 months follow-up. The intervention group will receive multiple weekly text messages that provide information, motivation, support to adhere to medications, quit smoking (if relevant) and recommendations for healthy diet and exercise. The primary endpoint is the percentage of patients who are adherent to cardioprotective medications and the key secondary outcomes are mean systolic blood pressure (BP) and low-density lipoprotein cholesterol. Secondary outcomes will also include total cholesterol, mean diastolic BP, the percentage of participants who are adherent to each cardioprotective medication class, the percentage of participants who achieve target levels of CV risk factors, major vascular events, hospital readmissions and all-cause mortality. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost-effectiveness.SummaryThe study will provide multicentre randomised trial evidence of the effects of a text message-based programme on cardioprotective medication adherence and levels of CV risk factors.Ethics and disseminationPrimary ethics approval was received from Western Sydney Local Health District Human Research Ethics Committee (HREC2012/12/4.1 (3648) AU RED HREC/13/WMEAD/15). Results will be disseminated via peer-reviewed publications and presentations at international conferences.Trial registration numberACTRN12613000793718; Pre-results.

Author(s):  
Katherine M Fagan ◽  
Anne Lambert-Kerzner ◽  
Evan P Carey ◽  
Eric J Del Giacco ◽  
Renee Mihalko-Corbitt ◽  
...  

Background: Prior studies have shown that depression may be associated with longitudinal medication non-adherence for patients with chronic cardiovascular disease. However, little is known about depression and medication adherence following acute coronary syndrome (ACS) hospitalization. Our objective was to assess whether depression was associated with longitudinal medication adherence following ACS among Veterans enrolled in a clinical trial designed to improve medication adherence. Methods: Patients included in the current analysis were enrolled in the MEDICATION study, which tested a multifaceted intervention versus usual care to improve medication adherence in the year following ACS hospitalization at 4 VA Medical Centers. Depression was assessed using the Patient Health Questionnaire (PHQ-9) prior to hospital discharge based on a score of ≥10. Medication adherence was assessed for 4 classes of cardioprotective medications (Statins, ACEI/ARBs, Clopidogrel, and Beta Blockers) in the 12-months following hospital discharge using pharmacy refill data. A proportion of days covered (PDC) was calculated based on the 4 classes of medications, and adherent patients were categorized based on a PDC ≥0.80. Then, we assessed the association between depression and medication adherence in the year after ACS hospitalization. Results: Of the 241 patients, the average age was 63.9 years, mean BMI was 30.9 kg/m 2 , and they had a number of comorbidities: 45.2% had diabetes and 65.6% had a history of coronary artery disease. The mean PHQ-9 score was 8.2 and 35.4% had depression (PHQ≥10) prior to discharge, with no difference in the prevalence of depression between treatment groups. In the year after ACS hospitalization, the mean PDC was 0.90 for all patients and there was no difference between depressed (PDC=0.91) and non-depressed patients (PDC=0.90). Among patients in the usual care group, there was also no difference in adherence between depressed (PDC=0.88) and non-depressed (PDC=0.86) patients. Conclusions: In this cohort of patients enrolled in a clinical trial, depression was present in 1 out of 3 patients during ACS hospitalization but not associated with medication adherence in the year after hospital discharge. A potential explanation for the lack of association between depression and adherence may be related to the overall high adherence rates found in the MEDICATION study. It will be important to assess whether depression is a marker of medication non-adherence in other ACS cohorts.


2021 ◽  
Vol 24 (4) ◽  
pp. 196-205
Author(s):  
Zahra Bagheri ◽  
Azim Azizi ◽  
Khodayar Oshvandi ◽  
Younes Mohammadi ◽  
Amir Larki-Harchegani

2021 ◽  
Vol 74 (4) ◽  
Author(s):  
Heather L Neville ◽  
Kelsey Mann ◽  
Jessica Killen ◽  
Michael Callaghan

Background: Despite ample evidence of benefit, adherence to secondary prevention medication therapy after acute coronary syndrome (ACS) is often suboptimal. Hospital pharmacists are uniquely positioned to improve adherence by providing medication education at discharge. Objective: To determine whether a standardized counselling intervention at hospital discharge significantly improved patients’ adherence to cardiovascular medications following ACS. Methods: This single-centre, prospective, nonrandomized comparative study enrolled patients with a primary diagnosis of ACS (January 2014 to July 2015). Patients who received standardized discharge counselling from a clinical pharmacist were compared with patients who did not receive counselling. At 30 days and 1 year after discharge, follow-up patient surveys were conducted and community pharmacy refill data were obtained. Adherence was assessed using pharmacy refill data and patient self-reporting for 5 targeted medications: acetylsalicylic acid, P2Y purinoceptor 12 (P2Y12) inhibitors, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β-blockers, and statins. Thirty-day and 1-year medication utilization, cardiovascular readmission rates, and all-cause mortality were also assessed. Results: Of the 259 patients enrolled, 88 (34.0%) received discharge counselling. Medication data were obtained for 253 patients (97.7%) at 30 days and 242 patients (93.4%) at 1 year. At 1 year after discharge, there were no statistically significant differences between patients who did and did not receive counselling in terms of rates of nonadherence (11.9% versus 18.4%, p = 0.19), cardiovascular readmission (17.6% versus 22.3%, p = 0.42), and all-cause mortality (3.4% versus 4.2%, p > 0.99). Overall medication nonadherence was 2.8% (7/253) at 30 days and 16.1% (39/242) at 1 year. Conclusions: Discharge medication counselling provided by hospital pharmacists after ACS was not associated with significantly better medication adherence at 1 year. Higher-quality evidence is needed to determine the most effective and practical interventions to ensure that patients adhere to their medication regimens and achieve positive outcomes after ACS. RÉSUMÉ Contexte : Malgré l’abondance de preuves démontrant ses avantages, l’adhésion à la pharmacothérapie de prévention secondaire après les syndromes coronariens aigus (SCA) est souvent « sous-optimale ». Les pharmaciens d’hôpitaux occupent une place unique pour améliorer l’adhésion en expliquant au patient l’usage des médicaments au moment du congé hospitalier. Objectif : Déterminer si une consultation standardisée au moment du congé hospitalier améliore significativement ou non l’adhésion à la pharmacothérapie cardiovasculaire après les SCA. Méthodes : Des patients ayant reçu un diagnostic primaire de SCA (de janvier 2014 à juillet 2015) ont été inscrits pour participer à cette étude comparative unicentrique prospective et non randomisée. Ceux ayant bénéficié d’une consultation standardisée par un pharmacien clinicien au moment du congé ont été comparés aux patients qui n’en n’avaient pas reçu. Trente jours et un an après le congé, des enquêtes de suivi du patient ont été menées et les données de renouvellement d’ordonnance des pharmacies communautaires ont été recueillies. L’adhésion a été évaluée à l’aide des données de renouvellement d’ordonnance et celles rapportées par le patient pour cinq médicaments ciblés : l’acide acétylsalicylique, les inhibiteurs P2Y purinoceptor 12 (P2Y12), les inhibiteurs de l’enzyme de conversion de l’angiotensine ou les antagonistes des récepteurs de l’angiotensine II, les antagonistes β et les statines. L’utilisation des médicaments à 30 jours et à un an, le taux de réadmission en raison d’un trouble cardiovasculaire et le taux de mortalité toutes causes confondues ont également fait l’objet d’une évaluation. Résultats : Sur les 259 patients inscrits, 88 (34 %) ont bénéficié d’une consultation au moment du congé. Des données concernant la médication de 253 patients ont été obtenues (97,7 %) à 30 jours et pour 242 patients (93,4 %) à un an. Un an après le congé, aucune différence statistique significative n’a été observée entre les patients ayant reçu ou non une consultation concernant la non-adhésion (11,9 % contre 18,4 %, p = 0,19), la réadmission en raison d’un trouble cardiovasculaire (17,6 % contre 22,3 %, p = 0,42), et le taux de mortalité toutes causes confondues (3,4 % contre 4,2 %, p > 0,99). La non-adhésion aux médicaments de manière générale se montait à 2,8 % (7/253) à 30 jours et à 16,1 % (39/242) à un an. Conclusions : La consultation concernant la médication donnée par les pharmaciens d’hôpitaux au moment du congé après les SCA n’était pas associée à un meilleur suivi de la médication un an plus tard. Des données probantes de meilleure qualité sont nécessaires pour déterminer les interventions les plus efficaces et pratiques pour que les patients adhèrent à leur régime médicamenteux et qu’ils obtiennent des résultats positifs après les SCA.


2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
M Abhyankar ◽  
B Majumder ◽  
DK Agarwal ◽  
KA Amarnath ◽  
MUKESH Jha ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: None. Background Hypertension (HTN) has been found to increase the risk of Covid-19 mortality when compared with normotensives, and those discontinuing the antihypertensive treatment have an additional fatality risk. Objective The survey was carried out to seek the opinion of Indian healthcare practitioners (HCPs) on the risk factors, challenges and management of HTN during the ongoing Covid-19 pandemic. Method This was a structured web-based objective questionnaire survey involving 2545 HCPs PAN-India. The survey comprised questions related to the risk factors for HTN, home blood pressure monitoring (HBPM), BP control, treatment, complications and challenges of uncontrolled HTN during Covid-19. Results This study showed that tobacco use, obesity and comorbidities are top three modifiable risk factors for HTN followed by emotional stress, during Covid-19 pandemic. A majority of HCPs (44%) reported that <30% of their hypertensive patients check BP at home while 36% and 20% reported that 30-50% and >50% of their patients respectively, practice HBPM. 20%, 63%, and 17% of HCPs respectively, reported that <20%, 20-40% and >40% of their patients presented with BP > 150/100 mmHg during lockdown. Of all the HCPs, 53% and 33% respectively, reported BP increase in <20% and 20-40% of their patients on monotherapy while 14% of HCPs reported BP increase in >40% of their patients on monotherapy during the lockdown. As compared to high dose monotherapy, dual and triple combination therapies (TDC) were selected as most preferred for the management of uncontrolled BP opted by 56% and 34% of the HCPs, respectively. The dual combination antihypertensives were ranked as angiotensin receptor blockers (ARB) + diuretic (DU) > ARB + calcium channel blockers (CCB) > ARB + beta-blocker. The TDC with ARB + CCB + DU was the most favored TDC antihypertensive therapy during Covid-19 era. Acute coronary syndrome was anticipated as the most common complication of HTN in the Covid-19 pandemic, followed by renal dysfunction, cerebral ischemia and cerebral hemorrhage reported by 47%, 17%, 14% and 14% of HCPs, respectively. Multiple challenges in HTN care during Covid-19 as opined by HCPs included BP measurement while avoiding the risk of infection (57%), advising treatment via teleconsultation (48%), dose modification (41%), patient compliance (32%) and transport-related issues (30%). Most of the HCPs believed that self-monitoring of BP (32%) and economical medicines (24%) can improve medication adherence in patients with HTN. Conclusion The study underlined that the provision of economic medicines, single pill combinations, doctor-patient digital connect, and patient education can help in improving medication adherence leading to better outcomes in patients with HTN during Covid-19.  The study also suggested the need to enhance HBPM and the use of ARB-based dual and triple combination therapies to improve BP control in patients uncontrolled on monotherapy during Covid-19 pandemic.


2019 ◽  
Vol 72 (11) ◽  
Author(s):  
Yulian H. Kyyak ◽  
Olga Yu. Barnett ◽  
Marta P. Halkevych ◽  
Olha Ye. Labinska ◽  
Hryhoriy Yu. Kyyak ◽  
...  

2019 ◽  
Vol 72 (11) ◽  
Author(s):  
Yulian H. Kyyak ◽  
Olga Yu. Barnett ◽  
Marta P. Halkevych ◽  
Olha Ye. Labinska ◽  
Hryhoriy Yu. Kyyak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document